Ivonescimab for advanced rare tumors: a safety & early-efficacy study
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these rare cancers: Paget's disease of the scrotum with sweat gland cancer, paraganglioma, pheochromocytoma, kidney angiomyolipoma, malignant PEComa, rhabdomyosarcoma, or another sarcoma (not rhabdomyosarcoma).
- Your cancer must have spread to other parts of the body (stage IV).
- You should be well enough to carry out daily activities (ECOG score 0–2).
- You need to have a tumor that can be measured on a CT or MRI scan, or a skin lesion that can be seen and measured.
- Your blood counts, kidney function, liver function, and blood clotting must be within acceptable ranges (no recent blood transfusions).
- You cannot have serious uncontrolled medical conditions like poorly controlled blood pressure, diabetes, heart problems, active infections, or severe allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that cannot be removed with surgery. The goal is to see if the drug can reduce or stop the growth of the tumors.
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Hear when a new Pheochromocytoma/Paraganglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.